logo

The Medicines Co. (MDCO)



Trade MDCO now with
  Date
  Headline
12/13/2018 9:51:43 PM The Medicines Company Prices $150 Mln Of Convertible Notes
12/11/2018 7:26:12 AM The Medicines Company Appoints Mark Timney As CEO
11/8/2018 7:15:57 AM The Medicines Co. Q3 Loss/shr From Cont. Ops. Widens To $0.70 From $0.10 Last Year
8/1/2018 7:21:19 AM The Medicines Co. Q2 Loss/shr Narrows To $0.74 From $5.53 Last Year
6/26/2018 7:28:42 AM Medicines Co Announces Presentation Of New Data From ORION-1 Phase II Trial At ADA 2018
5/7/2018 10:50:45 AM Medicines Reports Inclisiran Data Showing Reductions In Harmful Subtypes Of Bad Cholesterol On Heart Attack And Stroke
4/25/2018 7:16:50 AM Medicines Co. Q1 Loss From Cont Ops $84.8 Mln Or $1.14 Per Share
3/27/2018 9:25:56 PM Medicines Company Names Christopher Visioli As CFO, Succeeding William O'Connor
1/8/2018 7:20:53 AM The Medicines Company Announces Closing Of Divestiture Of Infectious Disease Business Unit To Melinta Therapeutics
1/8/2018 7:11:43 AM Melinta Therapeutics Completes Acquisition Of The Medicines Company’s Infectious Disease Business
8/31/2016 7:42:52 AM RBC Capital Markets Is Increasing The Medicines Co. (MDCO) 2016 Estimate To -0.74 From -0.75
2/18/2016 8:47:35 AM RBC Capital Markets Is Increasing The Medicines Co. (MDCO) 2016 Estimate To -4.34 From -5.48
1/30/2015 11:57:55 AM RBC Capital Markets Is Increasing The Medicines Co. (MDCO) FY16 Rev. Estimate To 572.7 M From 563.5 M
1/30/2015 11:57:41 AM RBC Capital Markets Is Cutting The Medicines Co. (MDCO) FY15 Rev. Estimate To 676.8 M From 688.6 M
1/30/2015 11:57:30 AM RBC Capital Markets Is Raising The Medicines Co. (MDCO) FY14 Rev. Estimate To 724.3 M From 720.2 M